Background -The acute response to bronchodilators in patients with chronic obstructive pulmonary disease (COPD) is modest; it has, however, been suggested that these patients may benefit from long term treatment. agonists may therefore result in an improvement in functional status, even in patients suffering from apparently nonreversible obstructive pulmonary disease. (Thorax 1995;50:750-754) 
Abstract
Background -The acute response to bronchodilators in patients with chronic obstructive pulmonary disease (COPD) is modest; it has, however, been suggested that these patients may benefit from long term treatment. Methods -To investigate the efficacy of salmeterol in smokers with moderate to severe COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 tg twice daily) and placebo in 63 patients with stable COPD (mean age 65 years). Prior to inclusion, all patients had a forced expiratory volume in one second (FEVy) of <60% of predicted and an improvement in FEVy of <15% following 400 ig inhaled salbutamol. Patients received four weeks of therapy with each of the treatment regimens. Assessment of efficacy was made with recording ofmorning and evening peak expiratory flow rates (PEF), respiratory symptoms, and use of rescue salbutamol. FEVy was measured before and after nebulised salbutamol prior to randomisation and at the end of each treatment period. Results -Morning PEF values were higher during the salmeterol than during the placebo period, although the mean treatment difference was small (12 /min (95% confidence limits 6 to 17)). No A total of 77 patients entered the run-in period of whom 66 met the final entry criteria and were randomised to receive treatment. Of these 66 patients three did not complete the study. One was unwilling to comply with the study protocol and two withdrew for personal reasons. On entry into the study all patients were taking inhaled 0 agonists and 19 were taking theophylline. Written informed consent was obtained from all patients and the protocol was approved by the ethics committee of Copenhagen and Frederiksberg counties.
PATIENT ASSESSMENTS
Patients attended the clinic on five occasions during the 12 weeks of the study and all evaluations were performed by one person (CSU). At the first visit demographic details were recorded and blood samples taken for biochemical and haematological analysis.
Spirometry
Patients were assessed at the same time of day at each visit. Salbutamol was omitted for four hours and study medication (salmeterol or placebo) for at least 24 hours before testing. The FEV, and forced vital capacity (FVC) were measured with a Vitalograph dry wedge spirometer using the highest of three recordings. The measurements were repeated 15 minutes after inhalation of 5 mg salbutamol solution from a jet nebuliser (Pari Inhalierboy). (table 1) were kept throughout the study period. Extra use of the ,B agonist (salbutamol) was also recorded.
Subjective patient evaluation At the completion of each treatment period the patients were asked to assess the subjective effect of the treatment on a scale from 1 to 4.
STUDY MEDICATION
The study was of a randomised, double blind, placebo controlled, crossover design. There was a two week run-in peijod in which patients took a salbutamol Diskhaler (0 4 mg per dose) when necessary for the relief of symptoms. This same rescue medication was also available during the treatment periods. After the run-in period patients who fulfilled the entry criteria were randomly allocated to receive either salmeterol (50 gg) twice daily for four weeks followed by placebo twice daily for four weeks or vice versa. Use of the study medication (salmeterol or placebo) was stopped on the day before the visit to the clinic. Patient compliance was checked by counting the unused medication at the end of each treatment period. CONCOMITANT MEDICATION At the start of the run-in period all oral, rectal, or inhaled , agonists (other than the salbutamol inhaler provided) and anticholinergic drugs were withdrawn. The patients on methylxanthines continued to use them at unchanged doses through the study. Short courses of oral corticosteroids were allowed during exacerbations. DATA 
ANALYSIS
To be included in the analysis of a variable patients had to have provided at least four days ofdata for that variable during the run-in period and data from at least 10 days in the last three weeks of each four week treatment period. In order to permit an analysis comparing the two treatment regimens data on the chosen outcome variables were tested for period effect and carryover effect.8 There was no washout period but, to minimise the possibility of carryover effect, the first week of each treatment period was excluded from the analysis.
Mean morning and evening PEF from data recorded on the diary cards were chosen as the primary end points before the study and therefore used as a basis for calculating sample size. Data from comparative studies of salmeterol were used to estimate the residual standard deviation ofmean daily PEF measure- ment. From these studies estimates of 35-401/ min were found for both morning and evening PEF and these data showed that the true standard deviation (SD) was unlikely to have exceeded 40 I/min. Using an SD of 40 /min it was calculated that a crossover study with 30 evaluable patients in each of the two sequence groups (60 patients in total) would have a power of 0 90 to detect a mean difference in PEF of 10 1/min at the 5% significance level.
For each of the two treatment periods the mean PEF values in the morning and evening and the mean difference between the morning PEF value and that of the previous evening were calculated for each patient. The treatment mean difference was estimated, together with 95% confidence limits, and tested for significance using a t test. The median difference between the two treatment periods in the percentage of days and nights with a symptom score of 0 and no additional salbutamol were calculated and subjected to Wilcoxon rank sum analysis. For each patient the median daytime and night time symptom score and the median number of additional daytime and night time salbutamol doses were obtained by sequence group, and Prescott's test was used to assess the treatment difference. Wilcoxon rank sum analysis was also used to assess the difference in median subjective patient scoring.
Results
The mean (SD) age of the 63 patients who completed the study was 65 (8) years and the mean (SD) number of pack years smoked was 44 (18) . The baseline FEV, as a percentage of predicted value ranged from 28% to 59%; no significant differences were found between the two sequence groups (table 2).
PEF MEASUREMENTS
Morning PEF values were significantly higher during the salmeterol period than during the placebo period. The mean (SE) morning PEF value during the salmeterol period was 238 (10) 1/min and the corresponding value during the placebo period was 226 (10) 1/min (table  3) . The mean treatment difference was 121/ min (95% confidence limits 6 to 17; p<0001) (figure). The mean evening value was 242 (10) /min during the salmeterol period and 237 (10) I/min during the placebo period (p>O 1). Diurnal variation in PEF, assessed as the difference between the morning PEF and that of the previous evening, was significantly more pronounced during the placebo period than during the salmeterol period (p<O001) although the magnitude of the mean treatment difference was small (7(2) 1/min).
FEV1 AND FVC MEASUREMENTS
The mean baseline FEVI, FVC, and FEV1/ FVC values were similar at the end of the two treatment periods and, likewise, no differences in mean reversibility in FEV, or mean FEVI, FVC, and FEV1/FVC values obtained after administration of salbutamol were found between the two treatment periods (table 3) .
SYMPTOM SCORE
Both the daytime and night time median symptom scores were significantly lower during the salmeterol period than during the placebo period (p<0001 for both; table 3), whereas no difference in median percentage of days or nights with a symptom score of 0 was found between the two treatment periods. RESCUE 
MEDICATION
The patients were allowed to use salbutamol for acute relief of respiratory symptoms during both treatment periods. Compared with placebo treatment with salmeterol was associated with significantly less use of rescue salbutamol both during the day and the night (p = 0-02 and p<0-001, respectively; table 3). The median percentage of nights when no additional salbutamol was used was significantly higher during the salmeterol period than during the placebo period (p<0 01), whereas the percentage of days when no rescue salbutamol was used did not differ between the two treatment periods. SUBJECTIVE 
ASSESSMENT
After the completion of each treatment period the patients were asked to assess the subjective effect of the treatment. The salmeterol period was rated significantly higher than the placebo period (p=0-01).
SIDE AND ADVERSE EFFECTS
The reported incidence and nature of both side effects and adverse events during the two treatment periods were similar. Fifty three of the 63 patients did not report any side or adverse effects at all during the whole study period. Tremor, sweating, and palpitations were registered as side effects in isolated cases; these symptoms disappeared following a reduction in the dose of rescue salbutamol to 0-2 mg. Hospital admission occurred in four cases, one patient during both treatment periods, one when on salmeterol, and one when receiving placebo. They were all given oral steroids for the acute exacerbation of their obstructive lung disease.
Discussion
The data presented from this double blind corssover study show that salmeterol (50 g twice daily) produced significantly greater improvements than placebo in PEF, including a reduction in the diurnal variation in PEF, in smokers with moderate to severe chronic obstructive pulmonary disease. Furthermore, the requirement for bronchodilator treatment to relieve symptoms during the day and night were reduced. The treatment was well tolerated with a low incidence of pharmacologically predictable side effects and adverse effects.
In most studies in which the effect of bronchodilators has been studied in patients with COPD the emphasis has been on the effect of the drug on spirometric values.9 This might not be the most appropriate measurement as the present study has shown, in keeping with findings in previous studies,1011 no significant increases in FEV, or FVC following regular treatment with salmeterol compared with placebo but significant differences in the subjective effect of active treatment and peak expiratory flow rates. These findings suggest that the therapeutic efficacy of bronchodilators in patients with COPD should probably be as- 
